Akouos, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Emmanuel Simons
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 645 Summer Street Boston MA United States of America 02210
- IPO Date
- Jun 26, 2020
- CIK
- 0001722271
- Website
- akouos.com
- Similar Companies
- Business
- Akouos, Inc. (AKUS) develops gene therapies to treat hearing loss, focusing on precision medicines that target genetic causes of hearing disorders through its Precision Otogenetics platform. The company offers investigational therapies including AK-OTOF for OTOF-mediated hearing loss and AK-2020 targeting the GJB2 gene for connexin 26 deficiency; it also advances additional programs addressing other monogenic forms of hearing loss via intracochlear delivery systems designed for safety and efficacy in pediatric and adult patients. Akouos operates in the biotechnology sector, primarily serving patients with severe to profound hearing loss across clinical development stages, with global research and development activities centered in the United States. Founded in 2016 and headquartered in Boston, Massachusetts, the company was acquired by Eli Lilly and Company in November 2022 for approximately $487 million, integrating Akouos' pipeline into Lilly's neuroscience portfolio as a wholly-owned subsidiary to accelerate gene therapy innovations for hearing restoration. This strategic acquisition marked a major shift from independent operations, enabling expanded clinical trials and manufacturing scale-up for its lead candidate AK-OTOF, which received FDA regenerative medicine advanced therapy designation in 2024. No significant partnerships, funding rounds, or new product launches have been reported independently since the acquisition, with ongoing efforts focused on Phase 1/2 trials and pipeline progression under Lilly's oversight.
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
Lilly and Akouos Announce Expiration of Akouos Tender Offer
SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.
AKOUOS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS
Why Is Akouos (AKUS) Stock Up 85% Today?
Why Akouos Stock Is on Fire Today
Eli Lilly to buy genetic medicine developer Akouos for $487 million
Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why
Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why
Akouos to Present at Bank of America 2022 Healthcare Conference
Akouos to Participate in Upcoming March Virtual Investor Conferences
Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting
Akouos to Present at Jefferies Gene Therapy/Editing Summit
Akouos to Present at Upcoming September Virtual Investor Conferences
Akouos' Hearing Loss Gene Therapy Poised To Receive Orphan Drug Tag In Europe
Akouos to Present at Upcoming August Virtual Investor Conferences
Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting
Akouos Appoints Dr. Kathy Reape as Chief Development Officer